Abstract: A cDNA clone (HEV1) encoding hevein was isolated via polymerase chain reaction (PCR) using mixed oligonucleotides corresponding to two regions of hevein as primers and a Hevea brasiliensis latex cDNA library as a template. HEV1 is 1018 nucleotides long and includes an open reading frame of 204 amino acids. The deduced amino acid sequence contains a putative signal sequence of 17 amino acid residues followed by a 187 amino acid polypeptide. The amino-terminal region (43 amino acids) is identical to hevein and shows homology to several chitin-binding proteins and to the amino-termini of wound-induced genes in potato and poplar. The carboxyl-terminal portion of the polypeptide (144 amino acids) is 74-79% homologous to the carboxyl-terminal region of wound-inducible genes of potato. Wounding, as well as application of the plant hormones abscisic acid and ethylene, resulted in accumulation of hevein transcripts in leaves, stems and latex, but not in roots, as shown by using the cDNA as a probe.
Type:
Grant
Filed:
May 26, 1992
Date of Patent:
March 21, 1995
Assignee:
Board of Trustees operating Michigan State University
Inventors:
Natasha V. Raikhel, Willem F. Broekaert, Nam-Hai Chua, Anil Kush
Abstract: The present invention relates to the application, as the stationary phase in affinity chromatography for the purification of the FGF type growth factors, of the polymers or copolymers onto which --SO.sub.3 H and --SO.sub.3 M groups are randomly bound, groups in which M denotes a physiologically acceptable metal, as well as, preferably, --SO.sub.2 R groups, in which R denotes a radical obtained by removal of a hydrogen atom from the amino group of an amino acid or an amino acid derivative.The invention relates also to the obtaining of a purified bFGF or aFGF growth factor, or a mixture of these growth factors, consisting in carrying out an affinity chromatography on a resin such as defined hereinabove, by carrying out an elution with a neutral pH buffer having an ionic strength equivalent to that of a 0.15 M to 2.5 M NaCl solution.
Type:
Grant
Filed:
April 15, 1988
Date of Patent:
June 16, 1992
Assignee:
Centre National de la Recherche Scientifique (CNBS)
Inventors:
Denis S. C. Barritault, Josette Badet nee Genissel, Jose P. Courty, Marie-Anne Dourges nee Jacquot, Danielle Gulino nee Debrac, Jacqueline Jozefonvicz nee Dorgebray
Abstract: There is provided a polypeptide having the following formula (I'), and which polypeptide is referred to as Glu-OC and a process for the preparation thereof.
Abstract: A method for solubilization and naturation of somatotropin using an aqueous alkaline solution results in lower dimer formation and eliminates denaturants and separate renaturation steps and agents.
Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps.
Abstract: The present invention encompasses a method for removing proteins from a solution containing polynucleotides and proteins comprising filtering the solution through a nitrocellulose membrane at neutral or basic pH.
Abstract: Mature human serum albumin is produced from a human serum albumin produced by a microbiological route in the form of fused protein ("pseudo-pro-HSA") containing an N-terminal peptide elongation.
Type:
Grant
Filed:
February 8, 1991
Date of Patent:
February 16, 1993
Assignee:
Genetica
Inventors:
Martine Latta, Jean-Francois Mayaux, Paolo Sarmientos
Abstract: Disclosed herein is a protein sweetener that has been isolated from Pentadiplandra brazzeana Baillon. The sweetener is thermostable, lysine rich, and has a relative long lasting taste. Also disclosed is a recombinant host capable of producing the sweetener in large quantities. Compositions of this sweetener with other sweeteners are also disclosed.
Abstract: The invention relates to muteins of human erythropoietin (EPO) in the carboxyl terminal region which are prepared by means of recombinant DNA techniques. These mutants have advantageous properties in comparison with human wild-type EPO.
Type:
Grant
Filed:
July 6, 1994
Date of Patent:
October 10, 1995
Assignee:
Behringwerke Aktiengesellschaft
Inventors:
Mathias Fibi, Gerd Zettlmeissl, Hans Kupper
Abstract: The particle size of amorphous protein material is reduced to uniform particulates without protein decomposition or loss of activity by passing the material through a fluid-energy mill.
Abstract: An almond N-glycosidase gene and genes associated therewith are described. Vectors integrated such genes therein, recombinant microorganisms transformed with said vectors, and a process for preparing the almond N-glycosidase using said recombinant microorganisms are also described.
Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to vaccine antigens containing the purified receptor proteins.
Type:
Grant
Filed:
January 10, 1991
Date of Patent:
August 25, 1992
Assignee:
University Technologies International, Inc.
Abstract: A non-toxic and non-cytolytic derivative of streptolysin O which retains at least one (preferably immunodominant) epitope is produced, and can be used especially in diagnostic tests for detecting of the presence of antibodies to Streptococcus pyogenes in a sample.
Abstract: A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.
Type:
Grant
Filed:
June 13, 1988
Date of Patent:
April 9, 1991
Assignee:
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Abstract: A method of recovering biologically active somatotropins which are produced as insoluble refractile bodies in transformed microorganisms which comprises dissolving refractile bodies in a denaturant and 2-amino-2-methyl-1-propanol, homogenizing, and diluting to fold.
Abstract: Substantially pure parathyroid hormone related protein (PTHrP) active in humoral hypercalcemia of malignancy and sub-units and fragments thereof. Antibody reagents capable of binding to epitopes of PTHrP. Methods and kits for the detection of PTHrP.
Type:
Grant
Filed:
June 14, 1991
Date of Patent:
October 24, 1995
Assignee:
The University of Melbourne
Inventors:
Thomas J. Martin, Jane M. Moseley, Bruce E. Kemp, Richard E. H. Wettenhall
Abstract: Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
November 26, 1991
Date of Patent:
November 18, 1997
Assignee:
Genetics Institute, Inc.
Inventors:
Rodney M. Hewick, Jack H. Wang, John M. Wozney, Anthony J. Celeste
Abstract: Microbially produced aprotinin and aprotinin homologs used for treating patients suffering from an excess release of pancreatic elastase, serum elastase or leukocyte elastase.
Type:
Grant
Filed:
October 2, 1989
Date of Patent:
July 16, 1991
Assignee:
Bayer Aktiengesellschaft
Inventors:
Ernst-August Auerswald, Werner Schroder, Eugen Schnabel, Wolfgang Bruns, Gerd Reinhardt, Michael Kotick